[go: up one dir, main page]

MA50418A - Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèse - Google Patents

Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèse

Info

Publication number
MA50418A
MA50418A MA050418A MA50418A MA50418A MA 50418 A MA50418 A MA 50418A MA 050418 A MA050418 A MA 050418A MA 50418 A MA50418 A MA 50418A MA 50418 A MA50418 A MA 50418A
Authority
MA
Morocco
Prior art keywords
synthesis
salts
methods
substituted heterocyclic
heterocyclic compounds
Prior art date
Application number
MA050418A
Other languages
English (en)
Inventor
John Emmerson Campbell
Kenneth William Duncan
James Edward John Mills
Michael John Munchhof
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of MA50418A publication Critical patent/MA50418A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
MA050418A 2017-10-18 2018-10-18 Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèse MA50418A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762573917P 2017-10-18 2017-10-18

Publications (1)

Publication Number Publication Date
MA50418A true MA50418A (fr) 2021-04-07

Family

ID=66173899

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050418A MA50418A (fr) 2017-10-18 2018-10-18 Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèse

Country Status (16)

Country Link
US (2) US20200247790A1 (fr)
EP (1) EP3697762A4 (fr)
JP (2) JP2021500334A (fr)
KR (1) KR20200101330A (fr)
CN (1) CN111417628A (fr)
AU (2) AU2018353122B2 (fr)
BR (1) BR112020007632A2 (fr)
CA (1) CA3079273A1 (fr)
CL (1) CL2020001009A1 (fr)
CO (1) CO2020005944A2 (fr)
EA (1) EA202090959A1 (fr)
IL (2) IL301746B2 (fr)
MA (1) MA50418A (fr)
MX (2) MX2020007152A (fr)
SG (1) SG11202003225YA (fr)
WO (1) WO2019079540A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110446495B (zh) 2017-02-17 2023-09-05 特维娜有限公司 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
CN118021814A (zh) 2017-04-21 2024-05-14 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
RS62818B1 (sr) 2017-10-18 2022-02-28 Incyte Corp Kondenzovani derivati imidazola zamenjeni tercijarnim hidroksi grupama kao inhibitorima pi3k-gamma
SI3847175T1 (sl) 2018-09-05 2024-05-31 Incyte Corporation Kristalinične oblike zaviralca fosfoinozitid 3-kinaze (pi3k)
CN114249785B (zh) * 2020-09-23 2024-04-05 常州方圆制药有限公司 一种2-腺苷n-吡唑的衍生物瑞加德松的制备方法
CN116406268A (zh) * 2020-10-27 2023-07-07 特维娜有限公司 δ-阿片样物质调节剂的结晶和无定形形式

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004272288B2 (en) * 2003-09-18 2008-11-13 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
MX362412B (es) * 2005-11-01 2019-01-15 Targegen Inc Inhibidores de biaril meta-pirimidina de cinasas.
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US9284272B2 (en) * 2014-03-28 2016-03-15 Abbvie Inc. Inhibitors of histone methyltransferase G9a
EP3154957B1 (fr) * 2014-06-16 2019-11-20 Fundacion para la Investigacion Medica Aplicada Nouveaux composés utilisés comme inhibiteurs doubles d'histone méthyltransférases et d'adn méthyltransférases
EP3157524A4 (fr) * 2014-06-23 2017-12-06 Genentech, Inc. Méthodes de traitement du cancer et de prévention de la résistance aux médicaments anticancéreux
KR20230130747A (ko) * 2016-04-15 2023-09-12 에피자임, 인코포레이티드 Ehmt1 및 ehmt2 저해제로서의 아민-치환된 아릴 또는 헤테로아릴 화합물
AU2017382830A1 (en) * 2016-12-19 2019-06-13 Epizyme, Inc. Amine-substituted heterocyclic compounds as EHMT2 inhibitors and methods of use thereof
AU2018243749A1 (en) * 2017-03-31 2019-11-21 Epizyme, Inc. Methods of using EHMT2 inhibitors
JP2021500327A (ja) * 2017-10-18 2021-01-07 エピザイム,インコーポレイティド 免疫療法にehmt2阻害剤を使用する方法

Also Published As

Publication number Publication date
CA3079273A1 (fr) 2019-04-25
EA202090959A1 (ru) 2020-07-13
SG11202003225YA (en) 2020-05-28
BR112020007632A2 (pt) 2020-09-29
EP3697762A4 (fr) 2021-04-07
AU2018353122B2 (en) 2023-11-23
IL301746B2 (en) 2025-01-01
CN111417628A (zh) 2020-07-14
US20220324851A1 (en) 2022-10-13
MX2024012124A (es) 2025-02-10
JP2023036991A (ja) 2023-03-14
IL273974A (en) 2020-05-31
MX2020007152A (es) 2020-12-10
CO2020005944A2 (es) 2020-07-31
IL301746B1 (en) 2024-09-01
WO2019079540A1 (fr) 2019-04-25
KR20200101330A (ko) 2020-08-27
CL2020001009A1 (es) 2020-12-18
IL273974B1 (en) 2023-04-01
EP3697762A1 (fr) 2020-08-26
US20200247790A1 (en) 2020-08-06
AU2024201165A1 (en) 2024-03-14
JP2021500334A (ja) 2021-01-07
IL301746A (en) 2023-05-01
AU2018353122A1 (en) 2020-06-04
IL273974B2 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
MA47233A (fr) Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation
MA50418A (fr) Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèse
EP3402799A4 (fr) Composés hétérocycliques utilisés comme inhibiteurs du vrs
CY1124187T1 (el) Ετεροκυκλικα αμιδια ως αναστολεις κινασης
MA51846A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
FR24C1009I2 (fr) Composés utilisés comme inhibiteurs de kinase
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
EP3389783A4 (fr) Nouveaux composés utilisés comme inhibiteurs de l'indoléamine 2,3-dioxygénase
MA46045A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA45669A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA44860A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA55633A (fr) Salicylamides de spiroheptane et composés associés utilisés comme inhibiteurs de rock
MX378499B (es) Compuestos antifungicos.
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
EP3331880A4 (fr) Dérivés de n-(pyridin-2-yl)-4-(thiazol-5-yl) pyrimidin-2-amine utilisés comme composés thérapeutiques
MA46531A (fr) Dérivés d'azétidine ou de cyclobutane 1,3-disubstitués utilisés comme inhibiteurs de la prostaglandine d synthase hématopoïétique (h-pgds)
JOP20190174B1 (ar) مثبطات jak1 انتقائية
MA40302A1 (fr) Dérivés de carbazole
MX394835B (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
MA51864A (fr) Méthodes d'identification de composés
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
MA50609A (fr) Énantiomères de thiazoles substitués utilisés comme composés antiviraux
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения